As disclosed herein, SIRPα is integral to immuno-evasion by many different cancer types as well as cancer resistance to therapies, and reducing SIRPα levels on can bolster antigen acquisition, processing, and presentation, decrease TME immunosuppression and thereby promote tumor-specific T cell activation to eliminate tumors and generate an adaptive immune response consisting of memory T cells, circulating antibodies, and plasma cells, all of which may be specific for neo-antigens in the original cancer. Therefore, disclosed are activated SIRPα.sup.low macrophages that are useful for treating cancers.

The antigen-presenting cell loaded with the cancer-specific tumor antigen epitope provided in the present invention, that is, a dendritic cell enables rapid and effective induction of differentiation and proliferation of cancer antigen-specific T cells, preferably memory T cells, and the memory T cells thus activated can treat a cancerous or neoplastic condition or prevent recurrence, progression, or metastasis of cancer while avoiding the defense mechanism of cancer cells.

The present disclosure provides the manufacturing of a monocyte that serves as a raw material for a dendritic cell for use in the manufacture of a therapeutic drug for adult T-cell leukemia and the like. The present disclosure provides: a method of producing a monocyte preparation from a blood preparation, the method comprising the step of obtaining a blood preparation from a subject, and the step of enriching the monocyte based on the specific gravity and cell size in the blood preparation; a monocyte preparation manufactured by the method; a dendritic cell induced from the monocyte preparation; and a product for regenerative medicine or the like. The present disclosure also provides treatment of an adult T-cell leukemia (ATL) patient.

The present invention relates to a method for providing information for cancer diagnosis or prognosis prediction by measuring the expression level of TIM-3 in CD11b+ cells.

In addition, the present invention relates to a composition for cancer diagnosis or prognosis prediction comprising an agent for measuring the expression level of TIM-3 in CD11b+ cells or uses thereof.

Since glial TIM-3 responds positively and uniquely to brain tumors and has specific intracellular and intercellular immune modulatory roles that may differ from TIM-3 in brain tumor microenvironment T cells, it can be effectively used in a composition or a method for providing information for cancer diagnosis or prognosis prediction.

Provided are a composition and method for inducing direct conversion from a somatic cell into a myeloid cell and use thereof, in which differentiation from a somatic cell into a myeloid cell can be efficiently induced through the expression of a single direct conversion inducer without undergoing the pluripotency stage of induced pluripotent stem cells, and thus, the composition can be widely used as an effective preventive and therapeutic agent for immune diseases.

The present disclosure provides histone deacetylase 6 (HDAC6)-activated macrophages, compositions comprising HDAC6-activated macrophages, methods of making HDAC6-activated macrophages, and methods of treating diseases, e.g., cancer, by administering a therapeutically effective amount of HDAC6-activated macrophages.

A monocytes derived signaling cells mixture is prepared by culturing buffy coats in a cell culture medium containing platelet-poor-plasma and collecting the cultured buffy coats and the cultured cell culture medium. The monocytes derived signaling cells mixture contains granulocytes, lymphocytes, fibrocytes and monocytes, in which the high ratio of the monocytes are CD16 positive monocytes. The monocytes derived signaling cells mixture is used in the improvement of liver function index of a subject.

The present disclosure provides compositions and methods for making and using engineered phagocytic cells that express a chimeric antigen receptor having an enhanced phagocytic activity for immunotherapy in cancer or infection.

Modified macrophage immune cells are provided for treatment of cancer and other diseases. In particular said macrophages express chimeric antigen receptors (CAR). The single chain variable fragment (scFv) may be directed against thymidine kinase 1 (TK1) or hypoxanthine guanine phosphoribosyltransferase (HPRT). The signaling domain may be derived from a Toll-like receptor (TLR).

The invention relates to a method of producing an iPSC-derived Kupffer Cell (IKC). The method may comprise providing a macrophage precursor (preMcp) derived from an induced pluripotent stem cell (iPSC). The macrophage precursor (preM-cp) may be cultured in the presence of a hepatic cue, such as a combination of primary human hepatocyte conditioned media and Advanced DMEM, thereby obtaining the iPSC-derived Kupffer Cell. The iPSC-derived Kupffer Cell may display a biological property of a primary Kupffer cell, such as a primary adult human KC (pKC). The biological activity comprises expression of a macrophage marker such as CD11, CD14, CD68, CD163, CD32, CLEC-4F, ID1 and ID3.